Anticoagulation After Bioprosthetic Mitral Valve Replacement

Initial Anticoagulation Strategy

The American College of Cardiology recommends warfarin therapy targeting INR 2.0-3.0 for at least 3 months and may extend to 6 months after bioprosthetic mitral valve replacement in patients at low bleeding risk 1, 2
The American College of Cardiology recommends that the early period carries substantially elevated stroke risk, justifying aggressive initial anticoagulation 2
The American Heart Association identifies hypercoagulable conditions as a risk factor requiring indefinite anticoagulation 2
The American Heart Association identifies an enlarged left atrium as a risk factor requiring indefinite anticoagulation 7

The American College of Cardiology recommends transition to low-dose aspirin (75-100 mg daily) alone after completing the initial 3-6 month warfarin course for patients without risk factors 1, 2
The American College of Cardiology recommends continuing warfarin indefinitely at INR 2.0-3.0 plus aspirin 75-100 mg daily for patients with risk factors 3, 4, 5, 6, 7

The American College of Cardiology recommends against using direct oral anticoagulants (DOACs) such as dabigatran or rivaroxaban for bioprosthetic valves 1
The American Heart Association recommends that patients on warfarin have substantially higher bleeding rates, though embolic event rates are similar 3, 4, 5, 6, 7
The American College of Cardiology recommends that low-dose aspirin is the alternative for patients unable to take warfarin, though this represents suboptimal protection 3, 4, 5, 6, 7